We narrowed to 203 results for: cell

#55636-AAV11

Ready-to-use AAV11 particles produced from pAAV-EF1a-Cre (#55636). In addition to the viral particles, you will also receive purified pAAV-EF1a-Cre plasmid DNA. EF1a-driven expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

July 16, 2025

Academic Institutions and Nonprofits only

#137119-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-Con/Fon-GCaMP6M (#137119). In addition to the viral particles, you will also receive purified pAAV-EF1a-Con/Fon-GCaMP6M plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of GCaMP6M. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Sept. 24, 2020

Academic Institutions and Nonprofits only

#121675-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

June 4, 2019

Academic Institutions and Nonprofits only

#55637-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1a-Flpo (#55637). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flpo plasmid DNA. EF1a-driven Flpo recombinase expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

March 18, 2024

Academic Institutions and Nonprofits only

#68720-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA (#68720). In addition to the viral particles, you will also receive purified pAAV-hSyn1-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA plasmid DNA. Cre-dependent GCaMP6s calcium sensor and bicistronic, physically separate mRuby2 expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

March 7, 2018

Academic Institutions and Nonprofits only

#52473-AAV1

Ready-to-use AAV1 particles produced from pAAV-synP-FLEX-splitTVA-EGFP-B19G (#52473). In addition to the viral particles, you will also receive purified pAAV-synP-FLEX-splitTVA-EGFP-B19G plasmid DNA. Helper virus for monosynaptic tracing with rabies virus. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Kohara et al Nat Neurosci. 2014 Feb;17(2):269-79. doi

Dec. 18, 2018

Academic Institutions and Nonprofits only

#137122-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Fon-GCaMP6F (#137122). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-GCaMP6F plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

March 12, 2021

Academic Institutions and Nonprofits only

#121675-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Dec. 15, 2020

Academic Institutions and Nonprofits only

#137122-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-Con/Fon-GCaMP6F (#137122). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-GCaMP6F plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

July 17, 2020

Academic Institutions and Nonprofits only

#121675-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Sept. 27, 2023

Academic Institutions and Nonprofits only

#137126-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Fon-sRGECO (#137126). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-sRGECO plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of cytosolic sRGECO calcium sensor. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#137158-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-ChRmine-mScarlet (#137158). In addition to the viral particles, you will also receive purified pAAV-nEF-ChRmine-mScarlet plasmid DNA. nEF-driven expression of ChRmine-mScarlet. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only

#137124-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-GCaMP6F (#137124). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-GCaMP6F plasmid DNA. EF1a-driven, Flp-dependent expression of GCaMP6f (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 18, 2021

Academic Institutions and Nonprofits only

#205997-AAV9

Ready-to-use AAV9 particles produced from pAAV_hSyn_WiChR_TS_mScarlet_ER (#205997). In addition to the viral particles, you will also receive purified pAAV_hSyn_WiChR_TS_mScarlet_ER plasmid DNA. hSyn-driven K+ selective channelrhodopsin for optogenetic inhibition of neurons. These AAV preparations are suitable purity for injection into animals.

Peter Hegemann, Johannes Vierock

Vierock et al Sci Adv. 2022 Nov 16:eadd7729.

July 30, 2025

Academic Institutions and Nonprofits only

#157970-AAV.A12.T

Ready-to-use AAV44.9(E531D) in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A01.T

Ready-to-use AAV2 in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#69571-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-C-CreintG (#69571). In addition to the viral particles, you will also receive purified pAAV-EF1a-C-CreintG plasmid DNA. EF1a-driven expression of optimized C-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-N-CretrcintG (Addgene catalog# 69570) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#69570-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-N-CretrcintG (#69570). In addition to the viral particles, you will also receive purified pAAV-EF1a-N-CretrcintG plasmid DNA. EF1a-driven expression of optimized N-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-C-CreintG (Addgene catalog# 69571) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A09.T

Ready-to-use AAV6 in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#137151-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-NpHR3.3-EYFP (#137151). In addition to the viral particles, you will also receive purified pAAV-nEF-NpHR3.3-EYFP plasmid DNA. nEF-driven expression of NpHR3.3-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 5, 2021

Academic Institutions and Nonprofits only